Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Celularity Inc (CELU)

Celularity adds Naveen Jain to board; director Diane Parks to resign

Neutral Impact 3 of 5 leadership Written later

Celularity Inc. appointed Naveen Jain, founder and CEO of Viome Life Sciences, to its Board of Directors, with his term to start after a Rule 14f-1 information statement waiting period. Diane Parks has notified the company she will resign from the Board as of that same effective time, and the filing says her decision was not due to any disagreement with the company.

Key points

  • Naveen Jain was designated under board designation rights tied to the September 2026 financing disclosed in an 8-K filed September 28, 2026.
  • Diane Parks will resign from the Board effective at the same time Jain's term begins.
  • Jain has not been appointed to any Board committee initially and will receive the standard non-employee director compensation.
  • The company expects to announce a fifth director shortly.

The filing

CompanyCelularity Inc (CELU)
Form8-K, current report
Filed with the SECSep 29, 2026, 5:25 PM ET
Accession number0001493152-26-044917

Items reported: 5.02 Director / Officer Change

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:43 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 29, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.